Chemotherapy for small cell bronchogenic carcinoma: CCNU and doxorubicin compared to CCNU, doxorubicin, vincristine, and procarbazine

N. J. Vogelzang, R. C. Trowbridge, D. H. Frenning, A. Theologides, B. J. Kennedy, D. R. Kelly, S. L. Ewing, G. J. Vosika

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Forty consecutive patients with small cell bronchogenic carcinoma were treated. The first 18 patients were treated with CNU and doxorubicin (Adriamycin) (CA). The next 22 patients were treated with CCNU, doxorubicin, procarbazine, and vincrisine (CAPO). Patient characteristics were similar. The partial plus complete response rate was 55% (ten of 18 patients) in th CA group compared to 41% (nine of 22 patients) in the CAPO group. The median survival from treatment was 28 weeks in theCA group compared to 33 weeks in the CAPO group. There were no drug-related deaths among the patients receiving CA compard to two definite and three probable drug-related deaths among the patients receiving CAPO. The addition of procarbazine and vincristine to CA for the treatment of small cell bronchogenic carcinoma resulted in increased toxicity and no survival bnefit.

Original languageEnglish (US)
Pages (from-to)997-1000
Number of pages4
JournalCancer Treatment Reports
Volume64
Issue number8-9
StatePublished - Dec 1 1980

Fingerprint Dive into the research topics of 'Chemotherapy for small cell bronchogenic carcinoma: CCNU and doxorubicin compared to CCNU, doxorubicin, vincristine, and procarbazine'. Together they form a unique fingerprint.

Cite this